輝隆股份(002556.SZ):減持數過半 解鳳祥等一致行動人累計減持158.92萬股
格隆匯6月1日丨輝隆股份(002556.SZ)公佈,公司於今日接到合計持股5%以上股東解鳳祥等人出具的《關於持股5%以上股東減持至5%以下的吿知函》及《簡式權益變動報吿書》。2022年3月21日至2022年5月31日,解鳳祥、解佩玲、範新江、唐東昇通過集中競價累計減持了158.92萬股,佔公司總股本的0.166584%,上述一致行動人預披露減持計劃的減持數量已過半。
此次權益變動後,上述一致行動人持有公司的股份數由49,288,825股減少至47,699,627股,持股比例由5.166582%下降至4.999998%,不再是合計持股5%以上股東。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.